Immunological and mutagenic actions of ribavirin monotherapy preceding combination therapy with interferon for patients with chronic hepatitis C

Antiviral Therapy

Volumn 14, Issue 4, 2009, Pages 513-522

  Ogawa, Koji ^a   Hige, Shuhei ^b   Nakanishi, Mitsuru ^b   Yamamoto, Yoshiya ^a   Chuma, Makoto ^b   Nagasaka, Atsushi ^c   Asaka, Masahiro ^b  

^a Hakodate Municipal Hospital   (Japan)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c SAPPORO CITY GENERAL HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA2B INTERFERON; CD30 ANTIGEN; INTERLEUKIN 10; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN; VIRUS RNA; ANTIVIRUS AGENT;

ADD ON THERAPY; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; AMINO ACID SEQUENCE; ARTICLE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; CLINICAL ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG POTENTIATION; DRUG RESPONSE; DRUG SENSITIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HEPATITIS C; HUMAN; LIVER FIBROSIS; MALE; MOLECULAR CLONING; MONOTHERAPY; MUTAGENICITY; PRIORITY JOURNAL; TH1 CELL; TH2 CELL; VIRUS LOAD; BLOOD; DRUG COMBINATION; DRUG EFFECT; GENETICS; HEPATITIS C VIRUS; IMMUNOLOGY; MIDDLE AGED; VIROLOGY;

ADULT; AGED; ANTIVIRAL AGENTS; CD4-POSITIVE T-LYMPHOCYTES; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; IMMUNITY, CELLULAR; INTERFERON ALFA-2B; MALE; MIDDLE AGED; RIBAVIRIN; RNA, VIRAL;

EID: 68549083515     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis 2000; 20:17-35.
2. Davis GL, Esteban-Mur R, Rustgi V, et al. Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. N Engl J Med 1998; 339:1493-1499.
3. Sidwell RW, Huffman JH, Khare GP, Allen LB, Witkowski JT, Robins RK. Broad-spectrum antiviral activity of virazole: 1-β-D-ribofuranosyl-1,2,4-triazole-3-carboxamide. Science 1972; 177:705-706.
4. Lau JYN, Tam RC, Liang TJ, Hong Z. Mechanism of action of ribavirin in the combination treatment of chronic HCV infection. Hepatology 2002; 35:1002-1009.
5. Dusheiko, G, Main J, Thomas H, et al. Ribavirin treatment for patients with chronic hepatitis C: results of a placebo-controlled study. J Hepatol 1996; 25:591-598.
6. Di Bisceglie AM, Shindo M, Fong TL, et al. A pilot study of ribavirin therapy for chronic hepatitis C. Hepatology 1992; 16:649-654.
7. Chemello L, Cavalletto L, Bernardinello E, Guido M, Pontisso P, Alberti A. The effect of interferon alfa and ribavirin combination therapy in naive patients with chronic hepatitis C. J Hepatol 1995; 23 Suppl 2:8-12.
8. Guidotti LG, Chisari FV. Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 2001; 19:65-91.
9. Mosmann TR, Sad S. The expanding universe of T-cell subsets: Th1, Th2 and more. Immunol Today 1996; 17:138-146.
10. +) T-cell response in acute hepatitis C. Gastroenterology 1999; 117:933-941.
11. Tsai SL, Liaw YF, Chen MH, Huang CY, Kuo GC. Detection of type 2-like T-helper cells in hepatitis C virus infection: implications for hepatitis C virus chronicity. Hepatology 1997; 25:449-458,
12. Tam RC, Pai B, Bard J. et al. Ribavirin polarizes human T cell responses towards a type 1 cytokine profile. J Hepatol 1999; 30:376-382.
13. Enomoto N, Sakuma I, Asahina Y, et al. Comparison of full-length sequences of interferon-sensitive and resistant hepatitis C virus 1b. Sensitivity to interferon is conferred by amino acid substitutions in the NS5A region. J Clin Invest 1995; 96:224-230.
14. Enomoto N, Sakuma I, Asahina Y, et al. Mutations in the nonstructural protein 5A gene and response to interferon in patients with chronic hepatitis C virus 1b infection. N Engl J Med 1996; 334:77-81.
15. Gale MJ, Jr, Korth MJ, Tang NM, et al. Evidence that hepatitis C virus resistance to interferon is mediated through repression of the PKR protein kinase by the nonstructural 5A protein. Virology 1997; 230:217-227.
16. Gale M, Jr, Blakely CM, Kwieciszewski B, et al. Control of PKR protein kinase by hepatitis C virus nonstructural 5A protein, molecular mechanisms of kinase regulation. Mol Cell Biol 1998; 18:5208-5218.
17. Martell M, Esteban JI, Quer J, et al. Hepatitis C virus (HCV) circulates as a population of different but closely related genomes: quasispecies nature of HCV genome distribution. J Virol 1992; 66:3225-3229.
18. Kato N, Hijikata M, Ootsuyama Y, et al. Molecular cloning of the human hepatitis C virus genome from Japanese patients with non-A, non-B hepatitis. Proc Natl Acas Sci U S A 1990; 87:9524-9528.
19. Paroni R, Sirtori CR, Borghi C, Kienle MG. High-performance liquid chromatographic determination of ribavirin in serum and urine and of its urinary metabolite 1,2,4-triazole-3-carboxamide. J Chromatogr 1987; 420:189-196.
20. Foster GR. Interferons in host defense. Semin Liver Dis 1997; 17:287-295.
21. Schlosser SF, Schuler M, Berg CP, et al. Ribavirin and alpha interferon enhance death receptor-mediated apoptosis and caspase activation in human hepatoma cells. Antimicrob Agents Chemother 2003; 47:1912-1921.
22. Martin J, Navas S, Quiroga JA, Pardo M, Carreno V. Effects of the ribavirin-interferon alpha combination on cultured peripheral blood mononuclear cells from chronic hepatitis C patients. Cytokine 1998; 10:635-644.
23. Fiorentino DF, Zlotnik A, Vieira P, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146:3444-3451.
24. Tsuruma T, Yagihashi A, Torigoe T, et al. Interleukin-10 reduces natural killer sensitivity and downregulates MHC class I expression on H-ras-transformed cells. Cell Immunol 1998; 184:121-128.
25. Kundu N, Fulton AM, Interleukin-10 inhibits tumor metastasis, downregulates MHC class I, and enhances NK lysis. Cell Immunol 1997; 180:55-61.
26. Shen X, Hong F, Nguyen VA, Gao B. IL-10 attenuates IFN-alpha-activated STAT1 in the liver: involvement of SOCS2 and SOCS3. FEBS Lett 2000; 480:132-136.
27. + T cells producing Th2-type cytokines. FASEB J 1995; 9:81-86.
28. Foschi FG, Gramenzi A, Castelli E, et al. Soluble CD30 serum level in HCV-positive chronic active hepatitis: a surrogate marker of disease activity? Cytokine 2000; 12:815-818.
29. Schiappa DA, Mittal C, Brown JA, Mika BP. Relationship of hepatitis C genotype 1 NS5A sequence mutations to early phase viral kinetics and interferon effectiveness. J Infect Dis 2002; 185:868-877.
30. Bracho MA, Moya A, Barrio E. Contribution of Taq polymerase-induced errors to the estimation of RNA virus diversity. J Gen Virol 1998; 79:2921-2928.
31. Asahina Y, Izumi N, Enomoto N, et al. Mutagenic effects of ribavirin and response to interferon/ribavirin combination therapy in chronic hepatitis C. J Hepatol 2005; 43:623-629.
32. Furusyo N, Kubo N, Toyoda K, et al. Helper T cell cytokine response to ribavirin priming before combined treatment with interferon alpha and ribavirin or patients with chronic hepatitis C. Antiviral Res 2005; 67:46-54.